drug

ALN-6222

1 story · latest Jul 30, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Alnylam Pharmaceuticals

Timeline

Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipeline

Jul 30Quarterly updateAlnylam Pharmaceuticals

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.